Skip to main content

Month: June 2021

Real People Investment Holdings Limited – Audited Annual Financial Statements for 2021, Amended Financial Covenants and Guidance Regarding Expected Bond Repayments

RPIH publishes its audited annual financial statements for the financial year 2021 The audited annual financial statements for 2021 is available to download at www.realpeoplegroup.co.za. Amended financial covenants Pursuant to the terms and conditions (as amended by a written procedure completed on 21 September 2020) (the “Terms and Conditions“) for the up to SEK 260,000,000 and up to NOK 135,000,000 senior unsecured callable bonds 2013/2028 with ISIN: SE0005392560 and NO0010689342 (the “Bonds“) issued by Real People Investment Holdings Limited (the “Issuer” or “RPIH“), the Issuer shall comply with the undertakings to uphold specified levels of financial ratios for relevant measurement periods from time to time, as prescribed in the senior unsecured loan agreement entered into between the...

Continue reading

System1, a Leading Omnichannel Customer Acquisition Platform, to Become a Publicly Listed Company Through a Business Combination With Trebia Acquisition Corp.

System1, a fast-growing and profitable omnichannel customer acquisition platform, will be valued at $1.4 billion in connection with the transaction.The growth capital provided by the transaction will accelerate System1’s leading position as a privacy-centric digital marketer, allow for investment in its proprietary technology platform (Responsive Acquisition Marketing Platform, or RAMP) and complete its acquisition of Protected.net.The transaction includes up to $600 million of fully committed financing, comprised of a debt commitment of up to $400 million and a $200 million equity backstop from Cannae Holdings, Inc. (NYSE: CNNE) that, together with a portion of the debt commitment, will be utilized as a backstop for potential future Trebia redemptions. This backstop combined with the potential for management to roll additional...

Continue reading

Better Choice Announces Pricing of Public Offering of Common Stock

NEW YORK, June 29, 2021 (GLOBE NEWSWIRE) — Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), an animal health and wellness company, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $5.00 per share. The aggregate gross proceeds to Better Choice from the public offering are expected to be $40 million prior to deducting underwriting discounts, commissions and other estimated offering expenses. Better Choice has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock to cover over-allotments, if any. Better Choice plans to use the net proceeds of this offering for general corporate purposes. Better Choice may also elect to use proceeds from this offering to acquire complimentary...

Continue reading

Pipeline Update Regarding COVID-19 test

June 29, 2021Announcement no. 13 Pipeline Update Regarding COVID-19 test BioPorto A/S (BioPorto) is currently developing a point-of-care test for SARS-CoV-2 on the proprietary gRAD platform designed to quickly and easily identify infected patients using a non-invasive sample. While indicative data from the process and studies in the US and Denmark supports the gRAD platforms strong capabilities as a technology for rapid testing, BioPorto has prioritized to secure a high sensitivity of more than 80% to further strengthen the clinical and commercial potential of the platform technology compared to other rapid test formats. “Over the last months we have increased sensitivity in our gRAD-based SARS-CoV-2 samples and studies, especially from the data developed and collected in Aarhus (DK). However, we are not yet at our target of 80%. Therefore,...

Continue reading

Wallbridge Continues Successful Expansion and Definition of High-Grade Shoots in Tabasco and Area 51 at Fenelon

TORONTO, June 29, 2021 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX:WM) (“Wallbridge” or the “Company”) today announced additional assay results from its current drilling program on the Fenelon Gold Property (“Fenelon” or the “Property”). Expansion drilling continues to reveal additional bulk mineable, near-surface mineralized corridors in the western part of Area 51, while definition drilling continues to define steep, high metal factor (gold grade multiplied by thickness) gold shoots within the Tabasco-Cayenne Zones (see 181-, 134- and 086- shoots on Fig. 1). Drilling is currently focusing on multiple areas, within the approximately 1.0 km by 1.2 km central portion of the Fenelon Gold System, to expand and better define the mineralization in support of the maiden mineral resource estimate (“MMRE”). Over 200,000 metres...

Continue reading

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference

LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O’Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021 at 4:30 pm ET. MediciNova will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann. About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and...

Continue reading

Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer

21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies Including Immunotherapy First Patient Dosed in Registration-Supporting IOV-LUN-202 Study in Second Line mNSCLC SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced clinical data for its tumor infiltrating lymphocyte (TIL) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) who enrolled in Cohort 3B of the ongoing basket study IOV-COM-202. Cohort 3B enrolled patients that had progressed on prior immune checkpoint inhibitor (ICI) therapy, including patients with oncogene-driven tumors who received...

Continue reading

Caisse Française de Financement Local: EMTN 2021-5

Issy les Moulineaux, 29 June 2021   Caisse Française de Financement Local has decided to issue on 30 June 2021 – EUR 1,000,000 -Fixed Rate Obligations Foncières due 30 June 2031. The dealer of the issue is named as stabilizing manager in the applicable Final Terms.   The Base Prospectus dated 11 June 2021 relating to the Euro Medium Term Notes Programme approved by the Autorité des Marchés Financiers and sent for notification to the Commission de Surveillance du Secteur Financier is available on the website of the issuer (www.caissefrancaisedefinancementlocal.fr), at the registered office of the issuer: 1-3 rue du Passeur de Boulogne – 92130 Issy Les Moulineaux Cedex, France, and at the office of the paying agent indicated in the Base Prospectus.   The Final Terms relating to the issue will be available on the website of the AMF...

Continue reading

Healthcare Supply Chain Management Market Size to Hit USD 5.40 Billion by 2028; Adoption of Blockchain Technology for Transaction to Boost Growth: Fortune Business Insights™

Top Players Covered in the Healthcare Supply Chain Management Market Research Report Are Henry Schein, Inc. (Melville, New York, United States), McKesson Corporation (Irving, Texas, US), Oracle (Austin, United States), Ascension (St. Louis, Missouri, US), Advocate Health Care, Inc. (Milwaukee, Wisconsin, US), Tecsys Inc. (Montreal, Canada), Banner Health (Phoenix, Arizona, US), Syft (Tampa, Florida), Ochsner Health System (Louisiana, US), Providence Health Service (Renton, Washington, US), and other key market players. Pune, India, June 29, 2021 (GLOBE NEWSWIRE) — Global Healthcare Supply Chain Management Market Size| 2021 Covid-19 Impact On Healthcare Industry Global Analysis By Size, Trends, Growth, Share, Business, Key Players, Merger, Statistics, Competitive Landscape, And Regional Forecast To 2028 is latest study published...

Continue reading

HIV Drugs Market to Hit USD 45.58 Billion by 2028, With 5.9% CAGR; Emergence of Antiretroviral Therapy as a Long-acting Suppression to Boost Growth, says Fortune Business Insights™

Key Prominent Players Covered in the HIV Drugs Market Research Report Are ViiV Healthcare (Research Triangle Park, U.S.) , Gilead Sciences, Inc. (Foster City, U.S.) , GlaxoSmithKline plc (Brentford, U.K.) , Merck Sharp & Dohme Corp. (Kenilworth, France) , Bristol-Myers Squibb Company (New York City, U.S.) , Janssen Pharmaceuticals, Inc. (Johnson & Johnson) (Beerse, Belgium) , Boehringer Ingelheim International GmbH (Ingelheim am Rhein, Germany) , AbbVie Inc. (North Chicago, U.S.) , Genentech, Inc. (F. Hoffmann-La Roche AG) (South San Francisco, U.S.) , Mylan N.V. (Canonsburg, U.S.) , Other Prominent Players Pune, India, June 29, 2021 (GLOBE NEWSWIRE) — The global HIV drugs market is set to gain traction from the increasing development of antiretroviral therapy to make it a first long-acting injectable formulation and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.